Quick Answer
HUTCHMED (China) Ltd reported Total Revenue of $548.51 million for fiscal year 2025.
HUTCHMED (China) Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $548.51M -13.0% |
$630.20M -24.8% |
$838.00M +96.5% |
$426.41M +19.7% |
$356.13M +56.2% |
$227.98M +11.3% |
| Revenue (ASC 606) | $548.51M -13.0% |
$630.20M -24.8% |
$838.00M +96.5% |
$426.41M +19.7% |
$356.13M +56.2% |
$227.98M +11.3% |
| Net Income | $456.91M +1111.0% |
$37.73M -62.6% |
$100.78M +127.9% |
-$360.83M -85.4% |
-$194.65M -54.8% |
-$125.73M -18.6% |
| Diluted EPS | $0.52 +1200.0% |
$0.04 -66.7% |
$0.12 +127.9% |
-$0.43 -72.0% |
-$0.25 -38.9% |
-$0.18 -12.5% |
| Total Assets | $1.75B +37.6% |
$1.27B -0.4% |
$1.28B +24.3% |
$1.03B -25.0% |
$1.37B +89.6% |
$724.12M +55.7% |
| Cash and Equivalents | $71.33M -53.7% |
$153.96M -45.7% |
$283.59M -9.5% |
$313.28M -17.0% |
$377.54M +60.2% |
$235.63M +94.5% |
| Long-Term Debt | $68.19M +14.7% |
$59.43M +23.3% |
$48.19M +166.2% |
$18.10M | — | $26.86M +0.2% |
| Stockholders Equity | $1.24B +62.9% |
$759.93M +4.0% |
$730.54M +19.7% |
$610.37M -38.2% |
$986.89M +103.9% |
$484.12M +68.1% |
| R&D Expense | $148.29M -30.1% |
$212.11M -29.8% |
$302.00M -21.9% |
$386.89M +29.4% |
$299.09M +71.1% |
$174.78M +26.5% |
| Operating Income | -$39.16M +10.4% |
-$43.70M -337.9% |
$18.38M +104.5% |
-$407.69M -24.2% |
-$328.32M -66.9% |
-$196.67M -34.3% |
- HUTCHMED (China) Ltd reported Total Revenue of $548.51 million for fiscal year 2025.
- HUTCHMED (China) Ltd showed a decrease of -13.0% in Total Revenue compared to the prior fiscal year.
- HUTCHMED (China) Ltd reported Revenue (ASC 606) of $548.51 million for fiscal year 2025.
- HUTCHMED (China) Ltd showed a decrease of -13.0% in Revenue (ASC 606) compared to the prior fiscal year.
- HUTCHMED (China) Ltd reported Net Income of $456.91 million for fiscal year 2025.
- HUTCHMED (China) Ltd showed an increase of +1111.0% in Net Income compared to the prior fiscal year.
- HUTCHMED (China) Ltd reported Diluted EPS of $0.52 per share for fiscal year 2025.
- HUTCHMED (China) Ltd showed an increase of +1200.0% in Diluted EPS compared to the prior fiscal year.
- HUTCHMED (China) Ltd reported Total Assets of $1.75 billion for fiscal year 2025.
- HUTCHMED (China) Ltd showed an increase of +37.6% in Total Assets compared to the prior fiscal year.
- HUTCHMED (China) Ltd reported Cash and Equivalents of $71.33 million for fiscal year 2025.
- HUTCHMED (China) Ltd showed a decrease of -53.7% in Cash and Equivalents compared to the prior fiscal year.
- HUTCHMED (China) Ltd reported Long-Term Debt of $68.19 million for fiscal year 2025.
- HUTCHMED (China) Ltd showed an increase of +14.7% in Long-Term Debt compared to the prior fiscal year.
- HUTCHMED (China) Ltd reported Stockholders Equity of $1.24 billion for fiscal year 2025.
- HUTCHMED (China) Ltd showed an increase of +62.9% in Stockholders Equity compared to the prior fiscal year.
- HUTCHMED (China) Ltd reported R&D Expense of $148.29 million for fiscal year 2025.
- HUTCHMED (China) Ltd showed a decrease of -30.1% in R&D Expense compared to the prior fiscal year.
- HUTCHMED (China) Ltd reported Operating Income of -$39.16 million for fiscal year 2025.
- HUTCHMED (China) Ltd showed an increase of +10.4% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: